GEP20032965B - Pharmaceutical Compound - Google Patents

Pharmaceutical Compound

Info

Publication number
GEP20032965B
GEP20032965B GEAP20016159A GEAP2001006159A GEP20032965B GE P20032965 B GEP20032965 B GE P20032965B GE AP20016159 A GEAP20016159 A GE AP20016159A GE AP2001006159 A GEAP2001006159 A GE AP2001006159A GE P20032965 B GEP20032965 B GE P20032965B
Authority
GE
Georgia
Prior art keywords
pharmaceutical compound
pharmaceutical
4methyl
benzodiazepine
thieno
Prior art date
Application number
GEAP20016159A
Other languages
English (en)
Inventor
David Edward Tupper
Jiban Kumar Chakrabarti
Terrence M Terrence Michael Hotten
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20032965(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GEP20032965B publication Critical patent/GEP20032965B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
GEAP20016159A 1990-04-25 2001-10-18 Pharmaceutical Compound GEP20032965B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009229A GB9009229D0 (en) 1990-04-25 1990-04-25 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GEP20032965B true GEP20032965B (en) 2003-05-12

Family

ID=10674942

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP20016159A GEP20032965B (en) 1990-04-25 2001-10-18 Pharmaceutical Compound

Country Status (33)

Country Link
EP (1) EP0454436B1 (cs)
JP (1) JP2527860B2 (cs)
KR (1) KR100195566B1 (cs)
CN (1) CN1028429C (cs)
AT (1) ATE127804T1 (cs)
AU (1) AU643267B2 (cs)
BG (1) BG61710B2 (cs)
CA (1) CA2041113C (cs)
CY (1) CY1900A (cs)
CZ (1) CZ279937B6 (cs)
DE (3) DE69112895D1 (cs)
DK (1) DK0454436T3 (cs)
ES (1) ES2078440T3 (cs)
FI (1) FI101379B (cs)
GB (1) GB9009229D0 (cs)
GE (1) GEP20032965B (cs)
GR (1) GR3017877T3 (cs)
HK (1) HK87596A (cs)
HU (2) HU212416B (cs)
IE (1) IE68401B1 (cs)
IL (2) IL97912A (cs)
LU (2) LU90009I2 (cs)
LV (1) LV10262B (cs)
MX (1) MX173791B (cs)
NL (2) NL970015I2 (cs)
NO (3) NO178766C (cs)
NZ (1) NZ237932A (cs)
PT (1) PT97446B (cs)
RU (1) RU2043992C1 (cs)
SI (1) SI9110739A (cs)
SK (1) SK279196B6 (cs)
YU (1) YU48049B (cs)
ZA (1) ZA913085B (cs)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817657A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
US5817656A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US6034078A (en) * 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
EP0582368B1 (en) * 1992-05-29 2001-01-24 Eli Lilly And Company Limited Thienobenzodiazepine derivatives for treatment of CNS disorders
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine
US6506746B2 (en) 1995-05-30 2003-01-14 Eli Lilly And Company Method for treating cognitive dysfunction
CN1131035C (zh) * 1995-05-30 2003-12-17 伊莱利利公司 治疗识别机能障碍的方法
DK0828494T3 (da) * 1995-05-30 2002-09-02 Lilly Co Eli Fremgangsmåde til behandling af kognitiv dysfunktion
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
WO1997023221A1 (en) * 1995-12-21 1997-07-03 Eli Lilly And Company Method for treating dermatitis
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
IL128956A0 (en) * 1996-09-23 2000-02-17 Lilly Co Eli Olanzapine dihydrate D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CN1268949A (zh) 1997-09-02 2000-10-04 吉富制药株式会社 稠合噻吩化合物及其医药用途
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
CN1239158C (zh) * 1997-09-30 2006-02-01 伊莱利利公司 2－甲基－噻吩并－苯并二氮杂䓬制剂
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
JP2004507548A (ja) 2000-08-31 2004-03-11 ドクター・レディーズ・ラボラトリーズ・リミテッド オランザピン水和物の調製方法、及びこれを結晶形態のオランザピンに変換する方法
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
AU2003237305A1 (en) 2002-05-31 2003-12-19 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
US20040063694A1 (en) * 2002-06-05 2004-04-01 Browder Monte R. Compound useful for the treatment of CNS disorders
PL199016B1 (pl) * 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) 2003-01-17 2004-09-16 Krka Tovarna Zdravil, D.D. Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
JP2007515428A (ja) 2003-12-22 2007-06-14 テバ ファーマシューティカル インダストリーズ リミティド オランザピンの合成方法
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
WO2005070937A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. A process for making olanzapine in a polymorph form i
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
PT1838716E (pt) 2005-01-05 2011-07-15 Lilly Co Eli Di-hidrato de pamoato de olanzapina
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) * 2006-09-11 2008-04-23 杭州盛美医药科技开发有限公司 一种奥氮平的中间体及其制备与应用
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (en) 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Improved processes for the synthesis of olanzapine
CN101168544B (zh) * 2007-11-16 2010-11-17 西南合成制药股份有限公司 奥氮平的制备工艺
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102532158A (zh) * 2010-12-17 2012-07-04 北大方正集团有限公司 一种合成奥氮平的方法
EP2486913A1 (en) 2011-02-14 2012-08-15 Labtec GmbH Rapidly disintegrating oral film formulation for Olanzapin
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN102225941B (zh) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 抗精神病药奥氮平的制备方法
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
JP5934004B2 (ja) * 2012-03-22 2016-06-15 株式会社トクヤマ 結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
EP2879519A1 (en) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. A method for increasing meat and milk production
WO2014021803A1 (en) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. Use of olanzapine in animals
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
KR101641902B1 (ko) 2015-06-24 2016-07-22 주식회사 네이처센스 농업회사법인 스트레스의 완화용 조성물
CN106265541A (zh) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 一种注射用奥氮平及其制备方法
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) * 1975-11-24 1978-11-22 Lilly Industries Ltd Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) * 1977-05-17 1980-10-29 Lilly Industries Ltd Benzodiazepine derivatives

Also Published As

Publication number Publication date
MX25502A (es) 1993-10-01
NZ237932A (en) 1993-08-26
KR910018387A (ko) 1991-11-30
EP0454436B1 (en) 1995-09-13
EP0454436A1 (en) 1991-10-30
ES2078440T3 (es) 1995-12-16
CZ279937B6 (cs) 1995-09-13
JPH0789965A (ja) 1995-04-04
PT97446B (pt) 1997-07-31
CA2041113A1 (en) 1991-10-26
AU7518691A (en) 1991-11-07
LV10262B (en) 1995-04-20
NL300078I1 (nl) 2002-03-01
CY1900A (en) 1991-04-24
KR100195566B1 (ko) 1999-06-15
IE911348A1 (en) 1991-11-06
AU643267B2 (en) 1993-11-11
HU212416B (en) 1996-06-28
BG61710B2 (bg) 1998-03-31
RU2043992C1 (ru) 1995-09-20
HU211575A9 (en) 1995-12-28
FI911986A0 (fi) 1991-04-24
ATE127804T1 (de) 1995-09-15
HUT60503A (en) 1992-09-28
NO911624L (no) 1991-10-28
IL112575A0 (en) 1995-05-26
DE19675046I2 (de) 2001-05-23
LU90869I2 (fr) 2002-02-21
DE69112895D1 (de) 1995-10-19
NO178766C (no) 1996-05-29
CN1056693A (zh) 1991-12-04
NL970015I2 (nl) 1997-09-01
NO178766B (no) 1996-02-19
HK87596A (en) 1996-05-24
LV10262A (lv) 1994-10-20
IL97912A0 (en) 1992-06-21
GR3017877T3 (en) 1996-01-31
NO1997005I1 (no) 1997-05-12
NO911624D0 (no) 1991-04-24
FI101379B1 (fi) 1998-06-15
SK279196B6 (sk) 1998-07-08
DE69112895T2 (de) 1996-03-07
HU911372D0 (en) 1991-10-28
SI9110739A (en) 1997-10-31
DE69112895T4 (de) 2009-11-12
CA2041113C (en) 1998-07-14
PT97446A (pt) 1992-01-31
YU48049B (sh) 1996-10-18
CS9101168A2 (en) 1991-12-17
FI911986L (fi) 1991-10-26
NO2001028I1 (no) 2002-01-28
MX173791B (es) 1994-03-25
YU73991A (sh) 1994-01-20
CN1028429C (zh) 1995-05-17
DK0454436T3 (da) 1995-11-13
IL97912A (en) 1995-10-31
LU90009I2 (fr) 1997-01-31
NL970015I1 (nl) 1997-06-02
GB9009229D0 (en) 1990-06-20
IE68401B1 (en) 1996-06-12
JP2527860B2 (ja) 1996-08-28
FI101379B (fi) 1998-06-15
ZA913085B (en) 1992-12-30

Similar Documents

Publication Publication Date Title
GEP20032965B (en) Pharmaceutical Compound
IL132763A0 (en) Novel compounds
GR3019450T3 (en) Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system
EP0495982A4 (en) Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient
CA2086434A1 (en) Quinuclidine derivatives
HUP9601884A3 (en) 6-(dimethylamino-methyl)-1-phenyl-cyclohexane compounds, their use as pharmaceutically active analgetic matarials and process for their preparation
IL112957A0 (en) Thieno [2,3-b] indoles, their preparation and pharmaceutical compositions containing them
EP0412554A3 (en) Sustained-release preparation for administration into brain
GB9212308D0 (en) Therapeutic compositions
ES2058029A1 (es) Proceso para la produccion de sales del acido clavulanico.
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
HUT45256A (en) Process for producing 1,3,4,9-tetrahydropyrano/3,4-b/indol-1-acetic acid derivatives and pharmaceutical composition containing them
HUT40667A (en) Process for preparing new thieno/2,3-d/imidazole derivatives and pharmaceutically acceptable acid addition salts thereof
TW221439B (cs)
MY101747A (en) Dihydroorotic acids derivative, processes for preparing the same
HUT53905A (en) Process for producing pharmacologically active triazolopyridine compounds active on central nervous system and pharmaceutical compositions comprising same
EP0207514A3 (en) 1,4-dihydropyridine derivatives, process for preparing them, pharmaceutical composition and use
HUT66017A (en) 1-phenyl-1a,2,3,4,6,7,12,12ba-octahydro-pyrimido[1',6',:1,2]pyrido[3,4-b] indole-derivatives and pharmaceutical composition containing them and process for their production
HU904983D0 (en) Process for producing imidazo(5,1-b)quinazoline-9-one derivatives and their pharmaceutically acceptible salts as well as process for producing pharmaceutical preparatives containing these active substances
PH25092A (en) A method of preventing and treating renal diseases
RU96124465A (ru) Способ лечения стойких дезадаптационных психовегетативных расстройств